No­var­tis co-opts Ho­mol­o­gy's gene-edit­ing tech for R&D pipeline

In the lat­est move to build up No­var­tis’ eye drug pipeline, the phar­ma gi­ant is sink­ing fresh cap­i­tal in­to a gene edit­ing com­pa­ny to work on se­cret tar­gets in oph­thal­mol­o­gy.

Fi­nan­cial de­tails weren’t dis­closed, but we do know that No­var­tis made an up­front pay­ment and an eq­ui­ty in­vest­ment in the start­up Ho­mol­o­gy Med­i­cines. The deal gets No­var­tis ac­cess to Ho­mol­o­gy’s gene edit­ing plat­form, which both com­pa­nies hope will lead to new drug tar­gets.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER